Novo Nordisk To Reveal The Huge Demand For Its Weight Loss Drugs
Novo Nordisk sees massive demand for weight-loss drugs Ozempic and Wegovy, boosting revenues sharply.
Pharma Giant Novo Nordisk will reveal the massive demand for
weight loss drugs, such as Ozempic and Wegovy. The Danish company has
experienced a significant boost in revenues, driven by the soaring demand for
its diabetes and weight-loss medications, Ozempic and Wegovy. According to an
analysis report, sales of £7.7billion are estimated between April and
June. Last year it was about £3.9billion for the same quarter.
Wegovy, the drug used to treat obesity, is an injection that
tricks the body into making it feel full. The medicine is available on the NHS
and is prominently famous in the U.S. Celebrities like Rebel Wilson. Over the
past year, a 64% rise has been noticed in shares. The current worth of Novo
Nordisk is worth £210billion.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Novartis India Appoints Dr. Chetan P. as Head of Medical, Regulatory and Pharmacovigilance
Hearzap Acquires Amplifon India's Hearing Healthcare Business in Strategic Consolidation Move
Discussion